GlassScriptPhysician profile
William Peacock
NPI 1588629893
$513,458.30
in general payments reported to CMS, 2019-2025
34 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $70K · 2021: $34K · 2022: $69K · 2023: $51K · 2024: $77K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $111K · Travel and Lodging: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Food and Beverage: $3,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $110,547.38 |
| Travel and Lodging | $49,802.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,509.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,161.68 |
| Food and Beverage | $3,509.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $86,772.91 | 2019-2025 | Stratus Cs, Advia Centaur Xp Analyzer |
| Instrumentation Laboratory Company | $63,070.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $54,568.96 | 2020-2025 | |
| Roche Diagnostics International LTD | $41,011.75 | 2021-2025 | |
| Astrazeneca Ab | $29,200.00 | 2020 | |
| Ortho-Clinical Diagnostics, INC. | $26,499.89 | 2024-2025 | Triage, Triage |
| Beckman Coulter, INC. | $26,189.87 | 2019-2024 | |
| Roche Diagnostics Corporation | $23,165.70 | 2019-2024 | |
| Abbott Laboratories | $21,688.13 | 2019-2025 | Id Now Instrument, Alinity |
| Janssen Pharmaceuticals, INC | $19,255.25 | 2019-2023 | Xarelto |
| Vifor Pharma, INC. | $14,588.15 | 2019-2023 | Korsuva, Veltassa |
| Janssen Scientific Affairs, LLC | $14,067.78 | 2019-2024 | Xarelto |
| Becton, Dickinson and Company | $13,957.20 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11,762.90 | 2019-2021 | |
| Diasorin S.P.A. | $11,613.32 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,094.28 | 2019-2023 | |
| Radiometer America, INC | $9,000.00 | 2024 | |
| Chiesi USA, INC. | $7,876.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,134.83 | 2019 | |
| Medicure Pharma INC. | $6,763.79 | 2019 | |
| Quidel Corporation | $5,956.94 | 2019-2023 | Triage |
| Astellas Pharma US INC | $3,988.01 | 2019 | |
| Novo Nordisk INC | $1,692.12 | 2025 | |
| Werfen USA LLC | $1,200.00 | 2020 | |
| Genetesis, INC. | $1,122.99 | 2022 | |
| Btg International INC. | $675.00 | 2025 | Aurlumyn |
| Nabriva Therapeutics, Plc | $602.24 | 2020 | |
| Gilead Sciences, INC. | $538.69 | 2023 | Veklury |
| Alexion Pharmaceuticals, INC. | $161.62 | 2022 | |
| Ceribell, INC. | $103.54 | 2025 | Pocket Eeg Device |
| Kyowa Kirin, INC. | $51.74 | 2024 | Crysvita |
| Portola Pharmaceuticals, LLC | $44.50 | 2020 | |
| Fisher Scientific Company L.L.C. | $39.05 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,830.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Peacock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.